Clinical Trial

Human Mass Balance Study of [¹⁴C]HRS-1893

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated June 18, 2026 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
HRS-1893-107 is a Phase 1, single-center, non-randomized, open-label, single-dose study designed to investigate the mass balance, metabolism, and pharmacokinetics of \[14C\]HRS-1893. The study aims to quantify the radioactive recovery rate, determine the primary excretion pathways, evaluate the whole blood-to-plasma radioactivity ratio, identify major metabolites, and characterize the pharmacokinetic (PK) profile of HRS-1893 and its metabolites. Safety and tolerability will be monitored throughout the trial.
Trial Details
NCT Number NCT07656779
Lead Sponsor Shandong Suncadia Medicine Co., Ltd.
Conditions Cardiomyopathies
Enrollment 6 participants
Start Date 2026-06
Primary Completion 2026-07 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2026-06-18